Affiliation:
1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer
Institute, Bethesda, MD, USA
Abstract
AbstractMedullary Thyroid Carcinoma (MTC) is a rare neuroendocrine cancer that accounts
for 1–2% of thyroid cancers in the United States (U.S.). While
most cases are sporadic, 25% of MTC cases are hereditary. These
hereditary cases occur in the setting of Multiple Endocrine Neoplasia Type 2A
(MEN2A) or 2B (MEN2B) driven by mutations in the Rearranged during
Transfection RET proto-oncogene. This article discusses hereditary MTC
in the setting of MEN2 and the treatment options available for it. The first
line treatment for this disease is typically a total thyroidectomy and tyrosine
kinase inhibitors. Two tyrosine kinase inhibitors, vandetanib and cabozantinib,
have been approved for treatment of advanced MTC, but options beyond those are
limited. However, several promising treatments are being studied, which are
discussed in this review.
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,General Medicine,Endocrinology, Diabetes and Metabolism
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献